Two days before a panel of the FDA’s outside advisors grill Novartis about its groundbreaking cell therapy under review, agency staffers released their own assessment of the product, which now goes by the name tisagenlecleucel. If approved for kids and young adults with acute lymphoblastic leukemia, or ALL, it would likely be the first so-called […]
NYS Entity Status
NYS Filing Date
MARCH 19, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC PROFESSIONAL CORPORATION
2014 - LIFE SYNERGY PHYSICAL THERAPY, P.C.
AROUND THE WEB
- Before Key Meeting, FDA Stresses Risks of Novartis CAR-T Cancer Therapy
By Alex Lash - Monday Jul 10, 2017
- 07 June, 2017 – Episode 622 – This Week in Science Podcast (TWIS)
By Kirsten Sanford - Friday Jun 9, 2017
Interview w/ Adrienne Godschalx re: Plant Defenses, Confirming Einstein, Void Life, We're All Moroccan?, Old Rock... Paintings, CAR-T Therapy Win, Monkey Cat!!!, Climate's All Connected, Magic Of Mucus, And Much More...
- 17 August, 2016 – Episode 580 – This Week in Science Podcast (TWIS)
By Kirsten Sanford - Friday Aug 19, 2016
Hawking Radiation Evidence?, Force Of Nature, Contrails Not Chemtrails, Gutting Ahead, Choosy Fish, Bully Fish, Fish Pee, Marsupial Lion Elbows, Talking About Life, Salty Beaches, Precision Targeting, The Light!, And Much More...
- 30 November, 2016 – Episode 595 – This Week in Science Podcast (TWIS)
By Kirsten Sanford - Thursday Dec 1, 2016
Weird Quantum Space, Space Eyes, Lucy In The Sky, Not Dead Yet, Old Genes, What The Frack?, Skin You're In, We All Gots Bugs, CRISPR Cures Hemophilia, Boiling Water, Life Choices, And Much More!!!
- “It’s Shame On Us If We Blow It”: Highlights From NY Seizes the Momentum
By Ben Fidler - Wednesday Jun 7, 2017
Mike Foley, a drug industry veteran and director of the Tri-Institutional Therapeutics Discovery Institute, has a pointed message for the New York life sciences industry: Don’t waste the moment. Changing the course of New York biotech has been a saga that dates back to the 1990s, and as Xconomy has detailed, progress has been made […]
- Boston Is Arguably the Heart of Biotech. But Who Makes It So? Have Your Say.
By Ben Fidler - Monday Jun 26, 2017
By the end of this year, for the first time, patients with certain deadly types of blood cancer might have a new option, CAR-T cell therapy, to prolong their life. Immunotherapy could further entrench itself as a mainstay of cancer treatment. Newer drugmaking methods—RNA interference and gene therapy—could get their first ever FDA reviews. Multiple […]